Advertisement

Topics

Faron getting to the bottom of the Traumakine conundrum

03:46 EDT 14 Jun 2019 | Proactive Investors

Faron expects to receive the interim results from the INFORAAA study of Traumakine in the near future, allowing a full review of all the Traumakine data with key opinion leaders, after which Faron will make the final decisions on Traumakine's development.

Original Article: Faron getting to the bottom of the Traumakine conundrum

NEXT ARTICLE

More From BioPortfolio on "Faron getting to the bottom of the Traumakine conundrum"

Advertisement
Quick Search
Advertisement
Advertisement